-
This is an open label extension of 306 subjects from a previously reported delayed-start phase III clinical trial of rasagiline in early Parkinson's disease. Clinical benefit observed at one year in the early vs. delayed-start arm was maintained over an average 3.6 ± 2.1 years observation, raising the question of whether earlier intervention with rasagiline results in better outcomes.
-
In this study, there is no correlation between the risk of recurrent stroke and the size of a PFO, the magnitude of the right-to-left shunt, or the presence of an atrial septal aneurysm.
-
-
Generalized autonomic failure (GAF) in the presence of a sensory neuropathy strongly suggests amyloidosis.
-
Excessive use of denture cream, which contains high concentrations of zinc, may cause copper deficiency nervous system syndromes.
-
The use of sustained pulsed dosing of intravenous immunoglobulin (IVIG) may be useful for treating multiple sclerosis (MS) patients with corticosteroid refractory optic neuritis.
-
The monoclonal antibody alemtuzumab, that targets the CD52 receptor on lymphocytes, reduced acute exacerbations and early disability by 70%.
-
Gingko biloba does not prevent Alzheimer's disease.
-
The JUPITER trial causes a stir; ACP practice guideline for antidepressant use; testosterone for low libido; continued shortage of Hib vaccine; FDA Actions.
-
This novel agent, which inhibits interactions between beta amyloid (Ab) and metal ions, holds promise as a therapeutic agent for Alzheimer's disease.